The Endurance 1 Trial (Endurance)
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 1 Trial)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The safety and tolerability of intravitreal aflibercept injections have been investigated in previous Phase I, I/II and III studies in AMD, RVO, and DME trials. Potential safety issues associated with the route of administration or the pharmacology of aflibercept in the study population include decreased BCVA, intraocular inflammation, intraocular infection, transient and/or sustained elevation of intraocular pressure (IOP), cataract development or progression, retinal or intravitreal hemorrhage, macular edema, retinal break or detachment, and arterial thromboembolic events (ATEs). Safety will be assessed by visual acuity, ophthalmic examinations, fluorescein angiograms, OCT, intraocular pressure, vital signs, and adverse event documentation.
To minimize the risks of intraocular infections, all injections will be performed employing sterile techniques as described in Appendix A. Study drug administration will be held for subjects who experience certain ocular events or infections. In the event any subject develops an adverse event in the study eye that is considered by the evaluating physician to be severe in intensity, serious consideration should be given to withdrawing the subject from the study.
The PI or designated Sub-Investigators will review all adverse events on an ongoing basis to determine causality and relationship to study drug and/or study procedures.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Enrolled and Completed VISTA DME (VGFT-OD-1009) clinical trial
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent
- Enrollment in the trial within 12 weeks of trial activation.
Exclusion Criteria:
- Prior treatment with anti-VEGF therapy in the study eye within 28 days of baseline
- Pregnant or breast-feeding women
Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly).
- Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: aflibercept
2mg, as needed, intravitreal administration. All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed. If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks. At week 12 through end of study, all subjects will be evaluated for focal laser treatment. |
All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study.
If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment.
Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
Andere Namen:
Wenn ein Patient rezidivierendes CR-DME hat, erhält er eine IVT-Aflibercept-Injektion
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Need for ongoing intravitreal aflibercept injections in the management of DME
Zeitfenster: 12 months
|
To assess the need for ongoing intravitreal aflibercept injections for subjects who were enrolled and completed the 3-year VISTA DME (VGFT-OD-1009) trial and to characterize long-term efficacy and safety of aflibercept intravitreal injections in the management of DME by evaluating mean number of injections in 52 weeks and proportion of subjects receiving 0 (zero) injections in 52 weeks.
|
12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Vision change
Zeitfenster: 12 months
|
Mean change in visual acuity from baseline to week 52.
|
12 months
|
|
Vision loss
Zeitfenster: 12 months
|
Proportion of subjects with gain or loss of 0 to 5 letters from baseline to week 52.
|
12 months
|
|
Change in central retinal thickness
Zeitfenster: 12 months
|
Mean change in central retinal thickness from baseline to week 52.
|
12 months
|
|
Entwicklung eines klinisch relevanten diabetischen Makulaödems
Zeitfenster: 12 Monate
|
Prozentsatz der Studienteilnehmer ohne klinisch relevantes diabetisches Makulaödem, das im SD-OCT vom Ausgangswert bis Woche 52 beobachtet wurde
|
12 Monate
|
|
Role of focal laser treatment in management of DME (Proportion of subjects that receive focal laser treatment and mean number of intravitreal aflibercept injections before and after receiving focal laser treatment.)
Zeitfenster: 12 months
|
Proportion of subjects that receive focal laser treatment and mean number of intravitreal aflibercept injections before and after receiving focal laser treatment.
|
12 months
|
|
Evaluation of Diabetic Retinopathy (Proportion of subjects with stable, worsened, or improved diabetic retinopathy as identified by eye examination and imaging.)
Zeitfenster: 12 months
|
Proportion of subjects with stable, worsened, or improved diabetic retinopathy as identified by eye examination and imaging.
|
12 months
|
|
Ocular and systemic adverse events
Zeitfenster: 12 months
|
Incidence and severity of ocular and systemic adverse events as identified by eye examinations, imaging, and subject reporting.
|
12 months
|
Mitarbeiter und Ermittler
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- REG-2014-11-006
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetisches Makulaödem
-
Mersin UniversityNoch keine RekrutierungNeuropathischer Schmerz | Krebsschmerz | Hartnäckiger Schmerz | Spinal Cord EdemaTürkei (türkiye)
-
Steno Diabetes Center CopenhagenMosaiques Diagnostics GmbHAnmeldung auf EinladungAlbuminurie | Geben Sie 2 DM ein | Typ 2 DM /Diabetic NephropathyDänemark
Klinische Studien zur Focal Laser Treatment
-
Almirall, S.A.AbgeschlossenSchuppenflechteDeutschland
-
Almirall, S.A.Abgeschlossen
-
Mayo ClinicPentax MedicalAbgeschlossen
-
Almirall, S.A.AbgeschlossenSchuppenflechteDeutschland
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development...RekrutierungAufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS)Vereinigte Staaten
-
University of FloridaEDAP-TMS Focal OneRekrutierung
-
Children's Hospital Medical Center, CincinnatiUniversity of Massachusetts, Amherst; St. Louis UniversityAbgeschlossenAufmerksamkeitsdefizitstörung mit Hyperaktivität | AufmerksamkeitsdefizitsyndromVereinigte Staaten
-
Focal Healthcare Inc.UnbekanntProstatakrebsVereinigte Staaten
-
EDAP TMS S.A.UnbekanntKrebs der ProstataFrankreich
-
EDAP TMS S.A.Institut National de la Santé Et de la Recherche Médicale, FranceAbgeschlossen